Sirtuin Activators and Weight Loss

Brief summary (registry, in English)

Obesity is a chronic, multifactorial disease associated with a high burden of metabolic, cardiovascular, and psychosocial complications. Despite extensive research, the long-term effectiveness of lifestyle-based weight-management strategies remains limited, and there is a growing interest in molecular pathways that may enhance metabolic flexibility and improve treatment outcomes. Among these pathways, the sirtuin (SIRT) family-particularly SIRT1 and SIRT3-has emerged as a promising target due to its involvement in mitochondrial biogenesis, energy expenditure, oxidative metabolism, and the regulation of insulin sensitivity. Bioactive compounds that activate sirtuins, including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), resveratrol, and selected polyphenols, have shown metabolic benefits in preclinical models; however, high-quality human trials remain scarce and inconsistent. This project aims to investigate the efficacy of a standardized sirtuin-activator supplement on body-weight reduction, metabolic health, and energy-balance regulation in adults with overweight and obesity. The trial will be a randomized, double-blind, placebo-controlled intervention lasting 24 days. Participants will be assigned to either the sirtuin-activator group or placebo, with both groups receiving standardized dietary plan to ensure consistent caloric intake. The primary outcome will be absolute and relative weight loss, while secondary outcomes will include changes in waist circumference, body-composition parameters, resting metabolic rate, glycemic markers, lipid profiles and physical functioning. A key novelty of this project lies in testing a multi-ingredient formulation designed to synergistically enhance sirtuin signaling, addressing limitations observed in studies using single-compound approaches. By integrating nutritional guidance, rigorous clinical monitoring, and advanced biomarker profiling, this research aims to generate high-quality evidence on whether sirtuin activators can meaningfully augment weight-loss interventions in humans.

What you commit to

• Study type: Interventional
• Participants enrolled: 45
• From 19 Jan 2026 to the primary completion date, 30 Jul 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.